Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Kosher-Certified Cannabis? These Companies Have You Covered
For those who keep kosher, most medical marijuana products on the market do not comply with the strict standards, leaving a large portion of the population under-served when it comes to weed. This gap in the market has created an opportunity, which companies like
The Hydropothecary Corporation (TSXV:THCX) (OTC:HYYDF) are capitalizing on.
Kosher Consumers: A Massive Market Opportunity
While the market for such products may not seem so large, it is. According to Lubicom Consuting, there's 12.35 million kosher consumers in the United States alone. As medical marijuana legalization spreads across areas with large Jewish populations, companies seeking to market kosher-certified cannabis need to comply with the strict requirements set fourth.
As we covered last October, Vireo Health was the first and only New York licensed medical marijuana products companies granted the kosher stamp of approval by the Orthodox Union.
While Vireo Health has kosher New Yorkers covered, The Hydropothecary Corp. has kosher Canadians on lock. As a licensed producer of medical marijuana under Health Canada's ACMPR, Hydropothecary is one of a small group of companies that can sell cannabis to patients throughout Canada.
While New York has well over 1 million Jewish residents, the Canadian Jewish population is certainly not small. According to The Centre for Israel and Jewish Affairs, a.k.a. CIJA, there's nearly 400,000 people that make up Canada's Jewish population. The advocacy group also notes that the median income for Canadian Jews (age 15+) is $30,670 CAD.
The population statistics above show that the move by Hydropothecary to obtain kosher certification could pan out to be extremely lucrative. Vaad HaKashrut director, Rabbi Levy Teitlebaum commented that "this is a rigorous, independent, third-party certification process that goes from A to Z. Hydropothecary's products not only qualify, but certification is gladly given because it's important for what's needed in this new sector."
The kosher certification covers Hydropothecary's "Decarb", the ready-to-consume activated marijuana powder product line, "Elixir" cannabis peppermint oil as well as the company's "H2" line of milled products.
"Kosher certification is important to Hydropothecary because it reflects our emphasis on rigorous testing, independent third-party oversight and our focus on easy-to-use product innovations. As the only medical marijuana company in Canada with current kosher-certified processed products, we take great pride in having the support of the Council for Kashrut," said Hydropothecary CEO and co-founder, Sebastien St-Louis.
Kosher Products Perform Better
If kosher food sales data are any indicator of kosher cannabis sales, this means big business for Hydropothecary and others who join them to serve this community. According to the Orthodox Union, "there is clear evidence that a kosher symbol boosts market share, that a kosher product can win more favorable shelf space, and that when positioned next to a competing non-kosher brand, a kosher product will do better by 20%. This data has remained constant even in smaller cities, far from city with heavy concentrations of kosher Jews."
What About Recreational Marijuana?
When asked about the kosher certification's applicability to recreational cannabis once it becomes legal in Canada, Rabbi Teitlebaum commented that "Medical products required for health and wellbeing are eligible for kosher certification. With legalization of marijuana for recreational use, however, we will have to consider the ethics of using a product simply for enjoyment."
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2017/10/18/Kosher-Certified-Cannabis-Hydropothecary-Vireo
agreed, it was long overdue. I think they got rid of a lot of retail investors today on the dip. The rest of this week should be very interesting!
3 Institutions Loading the Boat with Shares of 22nd Century Group?
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2017/10/18/XXII-3-Institutions-Loading-the-Boat-with-Shares-of-22nd-Century-Group
With the recent news surrounding 22nd Century Group, Inc. (NYSE:XXII) including the analyst upgrade from Chardan, positive phase III study results, a recent capital raise, and of course their incredibly valuable patent portfolio, and more investors have been wondering which institutions are investing their capital into the company.
We did some digging to highlight three institutions that are loading the boat with shares of XXII. Company insiders aside, the three biggest ownership increases in XXII have been from the following three asset managers:
CVI Investments, Inc.
As of recent data from WhaleWisdom, shares of XXII represent 23.55% of CVI Investments' portfolio. Now holding 7,070,707 shares of 22nd Century Group as of the most recent filing, CVI's stake is currently worth approximately $18,666,666.48.
Heights Capital Management, Inc., the investment manager to CVI Investments, Inc., is "a private equity and venture capital arm of Susquehanna International Group, LLP specializing in private investments in public equity in emerging growth companies. The firm typically invests in all the sectors with a particular focus on healthcare and technology companies," according to Bloomberg.
REST OF ARTICLE HERE
IGC on a nice little run!
So IGC is finally up 12% today. Could really run to on this news, also they are having their first shareholder meeting in 2 years next month. DEF worth a look at.
Here is the news they have popped on: https://www.dailymarijuanaobserver.com/single-post/2017/10/18/IGC-to-Commercialize-Alheimers-Drug-via-Medical-Dispensaries
Aphria to Raise $80 MM for Expansion and Strategic Investments
This morning, Aphria Inc. (TSX:APH) (OTC:APHQF) announced that it has entered into an agreement with Clarus Securities Inc., on behalf of a syndicate of underwriters, in which the syndicate of underwriters have agreed to purchase, on a "bought deal" basis, 11,034,500 common shares of the company at a price of $7.25 CAD per share. Aggregate gross proceeds to Aphria will be $80,000,125 CAD, equivalent to approximately $63,808,099.70 USD based on current foreign exchange rates.
With a last trade price of $7.92 CAD per share of Aphria, this represents a $0.67 CAD per share or 9.24% underwriter spread.
Additionally, the company has agreed to grant the underwriters an over-allotment option to purchase up to an additional 1,655,175 common shares at the $7.25 CAD per share offering price, exercisable in whole or in part at any time for a period ending 30 days from the closing of the offering. In the event the over-allotment option is exercised in full, the aggregate gross proceeds of the offering will be $92,000,144 CAD.
Based on the release, we expect the offering to close on or about November 7, 2017 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX Exchange.
Aphria intends to use the net proceeds from the offering for the development of infrastructure such as the purchase of capital and other equipment, as well as the expansion of its geographic footprint in Canada and other strategic investments, and for general working capital purposes.
This announcement comes on the heels of numerous capital raise efforts by other Canadian Licensed Producers such as Aurora Cannabis Inc. (TSX:ACB) (OTC:ACBFF) and more.
Invictus Provides Update on Canadian Recreational Cannabis Legalization
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2017/10/17/Invictus-Provides-Update-on-Canadian-Recreational-Cannabis-Legalization
Vancouver, B.C. - Oct. 17, 2017 --/ D.M.O. Newswire /-- INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (TSXV:IMH) (OTC:IVITF) (FRA:8IS1) updated shareholders that it is taking steps to monitor the government policy development process in advance of the legalization of recreational cannabis that is expected in July 2018.
“There are a number of authorities across the country that are developing policies and regulations to support the successful legalization of recreational cannabis. Invictus MD is monitoring these jurisdictions and will engage officials when necessary,” stated Dan Kriznic, Chairman and CEO of Invictus MD.
Invictus MD in Ontario
Invictus MD has been closely monitoring the recreational cannabis framework released by the Ontario government. Some highlights of Ontario’s proposed cannabis framework are:
Ontario will mirror the Liquor Control Board of Ontario model for retail sales
Purchase and consumption age will be 19 years old
Cannabis will not be sold alongside alcohol or in the same location
Current private dispensaries are illegal and will be shut down
Recreational cannabis use will be permitted in private residences only for now
Ontario will operate a scale up approach to storefront retail locations with 40 stores initially, 80 stores by the end of the first year and 120 stores by 2020
Online access will be available at the outset
Retail locations will resemble the early days of LCBO locations where product is not displayed and kept behind the counter for ordering
The new entity will only purchase from federally licensed producers within Canada
The government is not speculating on supply and possible increases in demand at the moment
The government is only permitting the smoking and ‘vaping’ of cannabis, no edibles at this time
Invictus MD in Alberta
Representatives from Invictus MD attended the Alberta Cannabis Secretariat’s Framework session in Edmonton last week where we were able to monitor stakeholder reaction to Alberta’s framework, including:
Oversight and enforcement of regulations will be carried out by the Alberta Gaming and Liquor Commission
The government plans to act as the wholesaler and clearinghouse for all cannabis sales through the AGLC using a “postage stamp” model for wholesaling the product – the wholesale price would be identical throughout the province.
The government wishes to ensure that both large and small producers can compete to supply the market with the AGLC by acting as a single buyer.
There has not been a decision as to whether the sale of cannabis should be made by government-owned stores, or by private retailers.
Purchase and consumption age will be 18 years old and will initially only be available in physical stores, not through online sales.
Use of the product will not be permitted at retail locations and are not planning to permit lounges and cafes
Legislative Update on Bill C-45 (Federal Cannabis Act)
Currently, Bill C-45, an Act Respecting Cannabis and to Amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed second reading in June 2017 and was referred to the Standing Committee on Health where they are reporting on the Bill with amendments.
IR Agreement
The Company has entered into an investor relation’s agreement (the “IR Agreement”) with Gold Standard Media LLC, a limited liability company existing under the laws of the State of Texas with an office at 1102 S. Austin Ave, #110-283, Georgetown, Texas, USA. The term of the IR Agreement is for a three-month public awareness campaign. In connection with the IR Agreement, the Company will be compensated one hundred and fifty thousand dollars.
Options Granted
The Company also reports that it has granted 1,535,000 incentive stock options to directors and consultants of the Company. The stock options are exercisable for a period of five years at an exercise price of $1.34 per share. The options were granted under and are subject to the terms and conditions of the Company's Stock Option Plan.
About Invictus MD Strategies Corp.
Invictus MD Strategies Corp. is focused on two main verticals within the Canadian cannabis sector, namely the Licensed Producers under the ACMPR, being its wholly owned subsidiary Acreage Pharms and its non-wholly owned affiliate AB Laboratories Inc.; along with Fertilizer and Nutrients through its non-wholly owned subsidiary Future Harvest Development Ltd.
For more information, please visit www.invictus-md.com.
On Behalf of the Board,
Dan Kriznic
Chairman & CEO
Larry A Heinzlmeir
Vice President, Marketing & Communications
604.537.8676
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Emerald Health Applies for 2 More Cultivation Sites Under ACMPR
VICTORIA, British Columbia, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. (“EHT”) (TSXV:EMH) (OTC:EMHTF), through Emerald Health Botanicals Inc. ("Emerald"), its wholly owned subsidiary and a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), has submitted license applications to Health Canada for approval of two new growing sites. Emerald is preparing for the large-scale production of cannabis in anticipation of legalization of the adult-use cannabis market on July 1, 2018.
In September, Emerald filed an application to Health Canada for its Pure Sunfarms’ Delta, BC facility, which is a partnership with Village Farms (TSXV:VFF). This partnership combines Emerald’s extensive medical cannabis growing experience and broad portfolio of cannabis genetics with Village Farms’ many decades of greenhouse growing expertise and large-scale, quality, low-cost production of an array of plant products and a currently producing, highly efficient 25-acre, 1.1 million square feet greenhouse facility. Emerald and Village Farms are retrofitting this greenhouse from tomato growing into a configuration optimized for large-scale cannabis cultivation. With a key goal of the partnership to be a large, very low-cost cannabis producer, Pure Sunfarms also optioned from Village Farms an additional 3.7 million square feet of existing highly-efficient greenhouse space in the same Delta complex.
In October, Emerald submitted its application for its own Richmond, BC, facility, for which Emerald is initially constructing 150,000 square feet of hybrid indoor and greenhouse growing space to produce cannabis in conjunction with legalized recreational use. This 32-acre site can be expanded to 1 million square feet. This facility will also house extraction and other processing capabilities as Emerald pursues value-added downstream product development.
In early October, Health Canada granted approval of Emerald’s second site application related to its Saanich facility, which is currently producing medical cannabis for sale as dried flower and oils, and serves as Emerald’s research and product development facility. This additional 7,000 square feet site, which is adjacent to the existing site, will allow expansion of this operation, subject to receiving the necessary approvals from the District of Saanich.
“As a licensed producer that is currently operating exclusively in Canada, submitting these license applications to Health Canada is a vital step as we execute our expansion plans,” said Chris Wagner, Chief Executive Officer of EHT. “We have appreciated our working relationship with Health Canada, which has already allowed us to secure a second site license, and look forward to working with them through their review of these additional applications."
Join us on our journey of making lives better through cannabis science.
About Emerald Health Therapeutics Inc.
Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) operates through Emerald Health Botanicals Inc. ("Botanicals"), a wholly owned subsidiary and Licensed Producer under the Access to Cannabis for Medical Purposes Regulations. Botanicals is authorized to produce and sell both dried medical cannabis flower and medical cannabis oil in Canada. Botanicals currently operates an indoor facility in Victoria, BC, and is progressing on expansion plans for a 32-acre property in Metro Vancouver and a partnership with Village Farms, called Pure Sunfarms, utilizing a 25-acre existing greenhouse complex in Delta, BC. Botanicals is one of Canada's most medically focused licensed producers, with a team highly experienced in life sciences product development and large-scale agribusiness. Its vision is to be a leading provider of cannabis products through its production capabilities, proprietary genetics, value-added products and branding, and superb customer experience. Emerald Health Therapeutics is associated with the Emerald Health group, which comprises multiple companies advancing diverse botanical, nutraceutical and pharmaceutical products that may provide wellness and medical benefits by interacting with the body’s endocannabinoid system.
For investor and media contacts:
invest@emeraldhealth.ca
def agree that they havent been spot on, but I have some real faith in XXII
Sites Confusing XXII Investors with Fake Price Target
Yesterday, Chardan's James McIlree reiterated a 'buy' rating on shares of 22nd Century Group, Inc. (NYSE:XXII) alongside a price target of $11.50 per share. While the term fake news is usually used by President Trump, it's the most fitting term to describe some of the XXII-related articles we've seen floating around today.
The report called 22nd Century Group "the solution to big tobacco's $30B problem." Chardan's "$11.50 price target is based on the company garnering royalty revenue for its technology on 10% of the US market share in the next five years." Risks to achieving the target price include "delays in the FDA process, ability to find partners for X-22, challenges in attracting contract manufacturing and selling product overseas and possibility of requiring additional capital."
REST OF THE ARTICLE
very true
recent news thats based on?
Aurora Cannabis Announces $6 Million Private Placement
TSX: ACB
VANCOUVER, Oct. 16, 2017 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora" or the "Issuer") (TSX: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that further to the Company's previously announced $60 million bought deal financing, as announced and upsized on October 10, 2017 (the "Bought Deal"), the Company has agreed to a one-time special accommodation for the benefit of its underwriters due to very significant demand for the Bought Deal, to proceed with a concurrent, non-commissioned, non-brokered private placement of up to 2,000,000 units of the Company (the "Units") at a price of $3.00 per Unit (the "Offering").
Each Unit, free of any commission to Aurora, will be comprised of one common share of the Company (a "Common Share") and one common share purchase warrant (a "Warrant"). Each Warrant will be exercisable to acquire one common share (a "Warrant Share") for a period of 3 years following the closing date of the Offering at an exercise price of $4.00 per Warrant Share, subject to adjustment in certain events.
If the Offering is subscribed for in full, it will provide Aurora with net proceeds of $6,000,000 due to the special and one-time commission free accommodation reached with its underwriters. The Common Shares and Warrants shall be subject to a 4 month hold period. Closing of the Offering is anticipated to occur at the same time as the closing of the Bought Deal, which is expected on or about November 2, 2017, and is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Toronto Stock Exchange and the applicable securities regulatory authorities.
The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as "Aurora Mountain", is currently constructing a second 800,000 square foot production facility, known as "Aurora Sky", at the Edmonton International Airport, and has acquired, and is undertaking completion of a third 40,000 square foot production facility in Pointe-Claire, Quebec, on Montreal's West Island.
In addition, the Company holds approximately 9.6% of the issued shares (12.9% on a fully-diluted basis) in leading extraction technology company Radient Technologies Inc., based in Edmonton, and is in the process of completing an investment in Edmonton-based Hempco Food and Fiber for an ownership stake of up to 50.1%. Furthermore, Aurora is the cornerstone investor with a 19.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis. Aurora also owns Pedanios, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union, based in Germany. The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and in state-of-the-art indoor gardening appliances for the cultivation of organic microgreens, vegetables and herbs in home and professional kitchens. Aurora's common shares trade on the TSX under the symbol "ACB".
On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth
CEO
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements include, but are not limited to, the successful completion of the Offering and the use of proceeds of the Offering and the Company's intention to continue international and domestic expansion. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. A more complete discussion of the risks and uncertainties facing the Company appears in the Company's Annual Information Form and continuous disclosure filings, which are available at www.sedar.com.
yea things are looking good!
still very bullish
Organigram Begins Re-Certification as Organic Cannabis Producer
https://www.dailymarijuanaobserver.com/single-post/2017/10/12/OGRMF-Organigram-Begins-Re-Certification-as-Organic-Cannabis-Producer
Organigram Begins Re-Certification as Organic Cannabis Producer
https://www.dailymarijuanaobserver.com/single-post/2017/10/12/OGRMF-Organigram-Begins-Re-Certification-as-Organic-Cannabis-Producer
Love to see this short squeeze!!!
Over 22% short interest (CLICK HERE)
WHAT A MORNING!